Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. September 2025 13:00 ET | Quelle: DelveInsight Business Research LLP

Chronic Gout Market to Witness Strong Growth by 2034 Owing to the Expected Launch of Therapies including mTOR Inhibitors and URAT1 Inhibitors | DelveInsight

New York, USA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Chronic Gout Market to Witness Strong Growth by 2034 Owing to the Expected Launch of Therapies including mTOR Inhibitors and URAT1 Inhibitors |...
14. Juni 2017 09:05 ET | Quelle: Horizon Pharma plc

Horizon Pharma plc Presents New Data Analyses Further Demonstrating Clinical Benefit of KRYSTEXXA® (pegloticase) in Patients with Uncontrolled Gout

DUBLIN, Ireland, June 14, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
14. Juni 2017 09:00 ET | Quelle: Horizon Pharma plc

Epidemiologic Study Findings Show Over 400 Percent Increase in Gout Patient Hospitalizations Since 1993

MADRID, Spain, June 14, 2017 (GLOBE NEWSWIRE) -- Results from a new study to be presented tomorrow at the Annual European Congress of Rheumatology (EULAR) 2017 show a 410 percent increase in...